Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1210/endo-54-2-228 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A review of the pharmacology, clinical outcomes, and real-world effectiveness, safety, and non-contraceptive effects of NOMAC/E2.
Eur J Obstet Gynecol Reprod Biol X
March 2024
Theramex HQ UK Ltd, 50 Broadway, 5th Floor, London SW1H 0BL, UK.
Article Synopsis
- * Nomegestrol acetate + 17β-estradiol (NOMAC/E2) is a combined oral contraceptive that effectively inhibits ovulation and has unique characteristics, as outlined in clinical and real-world studies.
- * The review discusses NOMAC/E2's pharmacological effects, clinical efficacy, safety data, and non-contraceptive benefits, finding it has a long half-life, effective pregnancy prevention, and low risk for serious safety issues like venous thromboembolism.
The link between daily affective complexity and anxiety is altered by oral contraceptive use.
Int J Psychophysiol
April 2024
University of Michigan, Department of Psychology, USA. Electronic address:
Affective complexity - the unique ways in which individuals' emotions covary and differentiate - is an important aspect of internalizing problems. For instance, daily affective complexity has been linked to anxiety increases in women and to decreases in men. The mechanisms underlying this gender difference have not been widely investigated, but a role for ovarian hormones is likely.
View Article and Find Full Text PDFCase report: prolonged durable clinical benefit and low toxicity from combination endocrine therapy in a patient with recurrent endometrial carcinoma.
Front Oncol
November 2023
Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Background: Endometrial carcinoma is the most common gynecologic cancer, with increasing incidence and mortality. Combination endocrine therapy comprised of tamoxifen and progestational agents has demonstrated promising results in treating recurrent disease. This case report describes the prolonged clinical benefit of treatment with tamoxifen and megestrol acetate in a woman with recurrent, metastatic endometrial endometrioid carcinoma positive for estrogen (ER) and progesterone receptors (PR).
View Article and Find Full Text PDF[Adaptation of the electron transport chain improves the biocatalytic efficiency of progesterone 17α hydroxylation].
Sheng Wu Gong Cheng Xue Bao
November 2023
College of Biotechnology, Tianjin University of Science & Technology, Tianjin 300457, China.
17α hydroxylase is a key enzyme for the conversion of progesterone to prepare various progestational drug intermediates. To improve the specific hydroxylation capability of this enzyme in steroid biocatalysis, the CYP260A1 derived from cellulose-mucilaginous bacteria Soce56 and the Fpr and bovine adrenal-derived Adx derived from str. K-12 were used to construct a new electron transfer system for the conversion of progesterone.
View Article and Find Full Text PDFNext step in the development of mesoprogestins: the preclinical profile of EC313.
Front Endocrinol (Lausanne)
September 2023
Evestra, Inc., Corporate Headquarters, Schertz, TX, United States.
Article Synopsis
- EC313 is a novel Selective Progesterone Receptor Modulator (SPRM) that exhibits both agonistic and antagonistic properties on the nuclear progesterone receptor, showing potential advantages over existing treatments.
- The estrogen-primed juvenile rabbit endometrium assay demonstrates that EC313 has stronger PR-agonistic effects than other mesoprogestins like Asoprisnil, indicating its effectiveness for conditions like uterine fibroids and endometriosis.
- In preclinical studies, EC313 effectively inhibits estrogenic activity and demonstrates superior anti-ovulatory effects without inducing premature labor, making it a promising candidate for further development in reproductive health treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!